Narek Shaverdian

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

Narek Shaverdian, Aaron Lisberg, Krikor Bornazyan et al. · The Lancet Oncology · 2017 · 1.1K citations · Full text

Radiation Medicine, Radiation Therapy, Medicine +9

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer

Amar U. Kishan, Audrey Dang, Alan J. Katz et al. · JAMA Network Open · 2019 · 302 citations · Full text

⁶⁸Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning

Jérémie Calais, Johannes Czernin, Minsong Cao et al. · Journal of Nuclear Medicine · 2017 · 260 citations · Full text

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

C. Jillian Tsai, Jonathan T. Yang, Narek Shaverdian et al. · The Lancet · 2023 · 214 citations · Full text

Adaptive Radiotherapy, Radiation Therapy, Medicine +9

A Multi-Institutional Experience of MR-Guided Liver Stereotactic Body Radiation Therapy

Stephen A. Rosenberg, Lauren E. Henke, Narek Shaverdian et al. · Advances in Radiation Oncology · 2018 · 157 citations · Full text

Adaptive Radiotherapy, Radiation Medicine, Hepatology +12